Sofinnova Management X

Mar 26, 2024 | streetinsider.com | Sofinnova Management X |Sofinnova Management X-A |a Delaware limited

1. SPY2. STOK3. AAPL4. ADBE5. F6. MSFT7. TSLA8. MTDR9. GME10. VKTX Tweet Share E-mail0 sharesSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549SCHEDULE 13D(RULE 13d-101)INFORMATION TO BE INCLUDED IN STATEMENTS FILEDPURSUANT TO RULE 13d-1(a)AND AMENDMENTS THERETO FILED PURSUANT TO RULE13d-2(a)(Amendment No. 4)*Vera Therapeutics, Inc. (Name of Issuer)Class A Common Stock, $0.001 par value(Title of Class of Securities)92337R101(CUSIP Number)Nathalie AuberSofinnova Investments, Inc.

Mar 18, 2024 | streetinsider.com | Sofinnova Management X

Privacy Preference CenterWhen you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies.

Jun 22, 2023 | advfn.com | Sofinnova Management X

FORM 4☐ Check thisbox if no longer subject to Section 16. Form 4 or Form 5obligations may continue. See Instruction 1(b).         UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIALOWNERSHIP OF SECURITIES                                                                                  OMBAPPROVALOMB Number: 3235-0287Estimated average burdenhours per response...

Jun 21, 2023 | advfn.com | Sofinnova Management X

FORM 4☐ Check thisbox if no longer subject to Section 16. Form 4 or Form 5obligations may continue. See Instruction 1(b).         UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIALOWNERSHIP OF SECURITIES                                                                                  OMBAPPROVALOMB Number: 3235-0287Estimated average burdenhours per response...

Feb 6, 2023 | streetinsider.com | Sofinnova Management X |a Delaware limited |James Healy |Sofinnova Management X-A

Form SC 13D/A Karuna Therapeutics, Filed by: Sofinnova Venture Partners X, L.P.February 6, 2023 6:02 AM EST Tweet Share E-mailGet inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. SECURITIES AND EXCHANGE COMMISSIONINFORMATION TO BE INCLUDED IN STATEMENTS FILEDPURSUANT TO RULE 13d-1(a)AND AMENDMENTS THERETO FILED PURSUANT TO RULE13d-2(a)Karuna Therapeutics, Inc. Common Stock, $0.0001 par value(Title of Class of Securities) Sofinnova Investments, Inc.